Sorafenib is prescribed for treatment of unresectable Hepatocellular Carcinoma (HCC), advanced Renal Cell Carcinoma (RCC) and Differentiated Thyroid Carcinoma (DTC).
Nexavar® registered sales of USD 69.7 million for the year ending December 2021 as per industry sales data.